Prurigo nodularis: New treatments on the horizon - 13/03/20
Doi : 10.1016/j.jaad.2019.02.061
Gil Yosipovitch, MD ⁎ 
Dr Phillip Frost Department of Dermatology and Cutaneous Surgery and Itch Center Miller School of Medicine, University of Miami, Miami, Florida
∗Correspondence to: Gil Yosipovitch, MD, University of Miami School of Medicine, 1600 NW 10th Ave, RMSB 2067, Miami, FL 33136.University of Miami School of Medicine1600 NW 10th AveRMSB 2067MiamiFL33136
Key words : dermatology, itch, pathogenesis, prurigo nodularis, TH2
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: Dr Yosipovitch has been a member of the scientific board of Menlo Therapeutics and a principal investigator in a Menlo-sponsored trial but was not involved in the current study. He is a consultant for and scientific advisory board member of Trevi, Sienna, Galderma, Sanofi Regeneron, Pfizer, Novartis, Dermavenda, Bayer, and Kiniksa and a principal investigator for Pfizer, Leo, Sun Pharma, Kiniksa, and Regeneron. |
|
| Reprints not available from the author. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 82 - N° 4
P. 1035-1036 - avril 2020 Retour au numéro
Article précédent
- What are we doing in the dermatology outpatient department amidst the raging of the 2019 novel coronavirus?
- Yusha Chen, Sushmita Pradhan, Siliang Xue
- Are financial incentives for interview swaps a candidate's right or an unethical practice?
- Madeline E. DeWane, Gloria Lin, Jane M. Grant-Kels
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?